Company

Tracer Biotechnologies

Tracer Biotechnologies develops blood and urine assays to monitor cancer through circulating tumor DNA.

About

Founded in 2023 and based in New York, Tracer Biotechnologies develops assays that detect circulating tumor DNA in blood and urine. Its Tracer assay supports ongoing molecular monitoring with fixed pricing for study time points and can detect tumor fractions as low as 10 parts per million. Customers include healthcare providers and research institutions. In December 2024, the company raised USD 10 million led by GKCC, LLC, with Caffeinated Capital, Exor Ventures, Great Oaks Venture Capital, Impatient Ventures, Pareto Holdings, and Quiet Ventures participating.

1Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in